Interleukin-6 Does Not Serve as a Clinical Marker or Treatment Target for Menstrual Irregularities
IL-6 is a physiological component of normal endometrial function that increases during the secretory phase and menstruation, but it has no established role in the clinical evaluation or management of menstrual irregularities. The provided evidence contains no guidelines recommending IL-6 measurement or targeting in menstrual disorders.
Understanding IL-6 in Normal Menstrual Physiology
IL-6 is expressed in endometrial tissue with a predictable pattern throughout the menstrual cycle 1, 2:
- Proliferative phase: Low expression in endometrial glands and stroma
- Mid-secretory phase (implantation window): 5-10 fold increase in glandular epithelium and uterine secretions 2
- Late secretory/menstrual phase: Progressive increase, with peak expression in stromal cells 1
This cyclical pattern reflects IL-6's role in normal endometrial remodeling and preparation for implantation, not pathology. Research demonstrates IL-6 inhibits endometrial stromal cell proliferation specifically during the secretory phase—a growth-regulatory function that maintains endometrial homeostasis 3, 4.
Clinical Evaluation of Menstrual Irregularities: The Evidence-Based Approach
When evaluating menstrual irregularities, guideline-recommended investigations focus on hormonal and structural assessments, not inflammatory markers like IL-6 5:
Essential Laboratory Evaluation (Days 3-6 of cycle):
- LH and FSH levels (average of three measurements 20 minutes apart): Assess for PCOS (LH/FSH ratio >2), premature ovarian failure (FSH >35 IU/L), or hypothalamic amenorrhea (LH <7 IU/mL)
- Mid-luteal progesterone (<6 nmol/L indicates anovulation)
- Testosterone (>2.5 nmol/L suggests PCOS or valproate effect)
- Prolactin (>20 μg/L, excluding postictal elevation)
- Fasting glucose/insulin ratio (>4 suggests insulin resistance)
Imaging:
- Pelvic ultrasound (days 3-9): Identify polycystic ovaries (>10 peripheral cysts, 2-8mm diameter)
Common Etiologies to Identify:
- PCOS (10-25% prevalence in temporal lobe epilepsy patients, 4-6% general population) 5
- Hypothalamic amenorrhea (12% in temporal lobe epilepsy vs 1.5% general population) 5
- Functional hyperprolactinemia (increased in epilepsy patients)
- Medication effects (antiepileptic drugs, particularly valproate causing weight gain and PCOS) 5
Why IL-6 Measurement Is Not Clinically Useful
Critical distinction: While research shows IL-6 varies with menstrual cycle phases 1, 2, 6, systemic IL-6 plasma levels show no sustained menstrual cycle-dependent changes 7. One study found median IL-6 levels of 0.68 pg/mL in the follicular phase with no significant variation throughout the cycle 7.
The disconnect between local endometrial IL-6 expression and systemic levels means:
- Blood IL-6 testing provides no diagnostic information about menstrual disorders
- IL-6 elevation in menstrual blood reflects normal physiology, not pathology 6
- No therapeutic interventions targeting IL-6 exist for menstrual irregularities
Management Framework
Management should address the underlying cause identified through proper evaluation 5, 8:
For PCOS-related irregularities:
- Weight management (weight gain triggers PCOS manifestation in predisposed women) 5
- Insulin sensitizers for metabolic dysfunction
- Hormonal contraception for cycle regulation (if no contraindications like antiphospholipid antibodies) 8, 9
For hypothalamic amenorrhea:
- Address psychological stressors 10
- Correct energy imbalance and excessive exercise 10
- Nutritional rehabilitation
For medication-induced irregularities:
- Consider alternative antiepileptic drugs with less metabolic impact 5
- Monitor for enzyme-inducing effects on sex hormone metabolism
Contraception considerations in women with menstrual disorders:
- Copper or progestin IUDs: Safe for all women with rheumatic/musculoskeletal diseases 9
- Combined hormonal contraceptives: Avoid in antiphospholipid antibody-positive patients 8, 9
- Progestin-only methods: Generally safe, though DMPA contraindicated if high osteoporosis risk 9
Common Pitfall to Avoid
Do not order IL-6 levels when evaluating menstrual irregularities. This test has no validated role in diagnosis or management and will not change clinical decision-making. Focus instead on the hormone panel and imaging outlined above, which directly identify treatable causes.